# Day Three

## 1. Complications of Blood Transfusion

### A. Classification

#### i. Procedure-related
- **Air embolism**
- **Infection** (viral, bacterial)
- **Phlebitis / extravasation**

#### ii. Blood-product-related
- **Allergic reactions**: urticaria → anaphylaxis (IgE-mediated against donor plasma proteins)
- **Acute hemolytic transfusion reaction (AHTR)**: ABO incompatibility → fever, flank pain, hypotension, DIC, acute renal failure
- **Febrile non-hemolytic transfusion reaction (FNHTR)**: cytokines or recipient anti-leukocyte antibodies → fever, chills
- **Transfusion-related acute lung injury (TRALI)**: donor anti-leukocyte Abs → neutrophil-mediated pulmonary capillary leak → non-cardiogenic pulmonary edema
- **Transfusion-associated circulatory overload (TACO)**: volume overload → hypertension, crackles, pulmonary edema
- **Delayed hemolytic reaction**: secondary recipient Abs → jaundice, anemia (days–weeks later)
- **Graft-versus-host disease (GVHD)**: viable donor lymphocytes engraft → rash, marrow aplasia, transaminitis

### B. Massive Transfusion-specific Complications

> Defined as:  
> - >10 units in 24 hours  
> - >50% blood volume in 1 hour  
> - Total blood volume in <48 hours

- **Citrate toxicity** → hypocalcemia → hypotension, prolonged QT, tetany
- **Dilutional coagulopathy**
- **Hypothermia** (cold stored units)
- **Hyperkalemia**
- **Metabolic acidosis** (lactic acid production + excess citrate from ACD)

---

## 2. Storage Anticoagulants & Shelf Life

| Anticoagulant | Composition                        | Storage duration |
|---------------|-------------------------------------|------------------|
| ACD           | Citrate, dextrose                   | 21 days          |
| CPD           | Citrate, phosphate, dextrose        | 21 days          |
| CPDA-1        | CPD + adenine                       | 35 days          |
| SAGM          | Saline, adenine, glucose, mannitol  | 42 days          |

---

## 3. Citrate Toxicity & Calcium

- **Mechanism**: Citrate chelates ionized Ca²⁺ → ↓ myocardial contractility, arrhythmia risk
- **Systole**: ↓ inotropy due to hypocalcemia
- **Diastole**: Rebound hypercalcemia (as citrate metabolizes)
- **Correction**: 1g IV calcium gluconate per 1L blood transfused

---

## 4. Transfusion Protocol

### Pre-transfusion
- Confirm indication (Hb threshold, bleeding, instability)
- Group & cross-match; verify unit ID, expiry, identities
- Establish IV access, record baseline vitals

### During transfusion
- Warm blood to prevent hypothermia
- Infuse slowly for first 15 min; monitor closely

#### If reaction occurs:
1. Stop transfusion
2. Start new IV line with 1L NS
3. High-flow O₂
4. IV hydrocortisone ± antihistamine
5. Send patient & donor blood for:
   - Coombs test
   - Cultures

### Post-transfusion
- Monitor vitals: every 30 min initially, then hourly × 4 h
- Consider furosemide (elderly, whole-blood), though **not routinely done** in our center

---

## 5. Clinical Case Vignettes

- **Case 1 (TACO)**: 68 y/o CHF patient → 4 PRBCs → dyspnea, crackles, HTN → treated with diuretics
- **Case 2 (FNHTR)**: 25 y/o multiparous woman → fever + chills 30 min post-transfusion → blood culture (-)
- **Case 3 (Citrate toxicity)**: 55 y/o trauma patient on massive transfusion → tetany, prolonged QT → IV calcium gluconate
- **Case 4 (TRALI)**: 40 y/o leukemia patient → acute hypoxemia 2 h post-transfusion, BNP normal → bilateral infiltrates
- **Case 5 (Delayed hemolytic)**: 30 y/o SCD patient → 3 weeks post-transfusion → jaundice, low Hb, ↑ LDH → positive DAT

---

## 6. Blood Donation Criteria

### General
- Age: **18–65 years**
- Weight: **≥ 50 kg**
- No donation in past 3 months
- No transfusion in past 6 months
- Not pregnant or <6 weeks postpartum

### Risk Exclusion
- High-risk behavior: tattoos, sex work, long-distance drivers
- No chronic infections or uncontrolled diseases (e.g., HIV, hepatitis, uncontrolled DM/HTN)

---

## 7. Cancer & Chemotherapy Fundamentals

### A. Overview
- Cancer: **clonal proliferation of malignant cells** with **local invasion** and **metastasis**
- Multimodal therapy: surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy
- Managed by: **multidisciplinary team (MDT)**

> Chemotherapy = 1 of 3 main pillars (with surgery and radiotherapy)

---

### B. Cell-Cycle Phases & Chemo Targets

| Phase            | Description                          | Chemo Targets & Examples                            |
|------------------|--------------------------------------|------------------------------------------------------|
| G0 (Quiescent)   | Resting phase                        | Evades chemotherapy                                  |
| G1 (Presynthetic)| Cell growth                          | CDK inhibitors (Palbociclib), hormonal agents        |
| S (Synthesis)    | DNA replication                      | Antimetabolites (Methotrexate, 5-FU, Cytarabine)     |
| G2 (Premitotic)  | DNA repair                           | Bleomycin, Etoposide                                 |
| M (Mitosis)      | Cell division                        | Mitotic inhibitors (Vincristine, Paclitaxel)         |

---

### C. Classification by Timing

- **Neoadjuvant**: Before surgery; shrinks tumor, stages disease, checks chemo response  
  - *Disadvantage*: Cancer may progress if unresponsive

- **Adjuvant**: After surgery; eradicates micrometastases

---

### D. Classification by Mechanism

- **Cell-cycle specific**:
  - Antimetabolites
  - Vinca alkaloids
  - Taxanes

- **Cell-cycle nonspecific**:
  - Alkylating agents (Cyclophosphamide, Chlorambucil)
  - Cytotoxic antibiotics (Doxorubicin)
  - **Mnemonic**: *CAN*
    - C = Chlorambucil
    - A = Cytotoxic Antibiotics
    - N = [Unspecified]

- **Targeted/Hormonal agents**:
  - Tamoxifen
  - Aromatase inhibitors
  - Imatinib
  - Finasteride

- **Immunomodulators**:
  - Checkpoint inhibitors
  - Levamisole (colon cancer adjuvant)

---

### E. Chemotherapy Logistics

- **Cycles**: Usually every 21 days; 6–8 cycles typical
- **Pre-infusion**:
  - H₂-blocker (Ranitidine)
  - Antiemetic (Ondansetron)
- **Delivery**: Central line preferred; 2 h infusion
- **Post-infusion**: Monitor 2–3 h, then follow up for delayed toxicity

## F. Clinical Case Vignettes (Oncology)

1. **Case 6:**  
   52-year-old woman with stage II breast cancer → neoadjuvant AC-T (doxorubicin + cyclophosphamide × 4 cycles, then paclitaxel) → 40% tumor reduction → lumpectomy performed.

2. **Case 7:**  
   65-year-old man with prostate cancer on LHRH agonist → develops hot flushes and osteoporosis risk → add bisphosphonate prophylaxis.

3. **Case 8:**  
   45-year-old woman, colon cancer adjuvant FOLFOX → on day 4 develops Grade 3 diarrhea → managed with loperamide + 20% dose reduction.

4. **Case 9:**  
   28-year-old Hodgkin lymphoma on ABVD → 6 months later CT shows pulmonary fibrosis → discontinue bleomycin + start pulmonary rehab.

5. **Case 10:**  
   38-year-old patient on high-dose cyclophosphamide → develops hemorrhagic cystitis → instituted MESNA + vigorous hydration prophylaxis.

---

## Classification of Chemotherapy Based on Mechanism of Action

### 1. Cell-Cycle Specific Agents  
| Class                         | Phase Targeted | Mechanism                                    | Examples                                                         |
|-------------------------------|----------------|----------------------------------------------|------------------------------------------------------------------|
| **Antimetabolites**           | S              | Inhibit DNA synthesis                        | Methotrexate, 5-FU, Cytarabine, 6-Mercaptopurine                 |
| **Vinca Alkaloids**           | M              | Inhibit microtubule polymerization           | Vincristine, Vinblastine                                         |
| **Taxanes**                   | M              | Stabilize microtubules, prevent disassembly  | Paclitaxel, Docetaxel                                            |
| **Topoisomerase Inhibitors**  | S & G2         | Inhibit topoisomerase I/II                   | Irinotecan (Topo I), Etoposide (Topo II)                         |

### 2. Non-Cell-Cycle Specific Agents  
| Class                   | Mechanism                                    | Examples                           |
|-------------------------|----------------------------------------------|------------------------------------|
| **Alkylating Agents**   | Cross-link DNA                               | Cyclophosphamide, Chlorambucil, Ifosfamide |
| **Cytotoxic Antibiotics** | Intercalate DNA, free radicals, inhibit topo | Doxorubicin, Daunorubicin, Bleomycin    |
| **Platinum Compounds**  | DNA cross-links                              | Cisplatin, Carboplatin              |

### 3. Hormonal Agents  
| Class                     | Mechanism                         | Examples                         |
|---------------------------|-----------------------------------|----------------------------------|
| **Anti-estrogens**        | Estrogen receptor antagonists     | Tamoxifen, Fulvestrant           |
| **Aromatase Inhibitors**  | Block peripheral estrogen synthesis | Anastrozole, Letrozole           |
| **Anti-androgens**        | Androgen receptor blockers        | Flutamide, Bicalutamide          |
| **5-α Reductase Inhibitors** | Inhibit T → DHT conversion       | Finasteride, Dutasteride         |

### 4. Immunomodulators  
| Agent               | Use                                   |
|---------------------|---------------------------------------|
| **Levamisole**      | Adjuvant with 5-FU in colon cancer    |
| **Thalidomide/Lenalidomide** | Multiple myeloma              |

---

## Triple Assessment in Cancer Diagnosis

1. **History & Physical Exam**  
2. **Imaging** (e.g., mammogram, CT, MRI, PET)  
3. **Tissue Diagnosis** (FNAC, core biopsy, excisional biopsy)  

> **Aim:** confirm diagnosis → assess spread → stage with TNM.

---

## Chemotherapy Protocol

- **Cycles:** typically every 21 days (6–8 cycles)  
- **Pre-infusion:** H₂-blocker (ranitidine), antiemetic (ondansetron)  
- **Delivery:** central line preferred; infuse over ~2 hours  
- **Monitoring:** observe 2–3 hours post-infusion, then routine follow-up for delayed toxicity  

---

## Side Effects of Chemotherapy

- **GIT:** diarrhea, mucositis → give H₂ blockers  
- **Alopecia:** hair loss  
- **Skin/Nail:** hyperpigmentation, melanonychia  
- **Pulmonary:** fibrosis (e.g., bleomycin)  
- **Bladder:** hemorrhagic cystitis (cyclophosphamide; prevent with MESNA)  
- **Cardiac:** cardiomyopathy (doxorubicin)  
- **Neurologic:** central neurotoxicity, cerebral edema  
- **Emesis:** nausea/vomiting → antiemetics (ondansetron)

---

## Patient Counseling

- Explain **diagnosis**, **stage**, and **treatment plan**  
- Discuss **prognosis** and **expected side effects**  
- Address **fertility**, **psychosocial support**, and **long-term follow-up**

